Therapeutic compounds and uses thereof
US-2019152949-A1 · May 23, 2019 · US
Late SV40 (LSF) inhibitors
US11420977B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11420977-B2 |
| Application number | US-201916530080-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 2, 2019 |
| Priority date | Aug 2, 2018 |
| Publication date | Aug 23, 2022 |
| Grant date | Aug 23, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention is directed to compositions, methods and kits for treatment of cancer, e.g. heptacellular carcinoma (HCC). In some embodiments, the present invention discloses the use of a small-molecule compounds of Formula (I)-(V) to inhibit tubulin methylation or to modulate chromatin or cytoskeleton modification in a cell.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound having the structure: and wherein the compound inhibits Late Simian Virus 40 Factor (LSF). 2. A method for treating cancer in a subject, the method comprising administering an effective amount of a compound of claim 1 to a subject in need thereof. 3. The method of claim 2 , wherein the cancer is selected from the group consisting of breast cancer, colon cancer, ovarian cancer, pancreatic cancer, lung cancer, kidney cancer, cancers of the hematopoietic system, cancers of the endometrium, cervical cancer, cancers of the upper digestive tract, stomach cancer, liver cancers and cancers of the small intestine. 4. The method of claim 3 , wherein cancer is hepatocellular carcinoma (HCC), colon cancer, pancreatic cancer, hematopoietic cancer or cervical cancer. 5. A method of inhibiting tubulin methylation or modulating chromatin/cytoskeleton modification in a cell, the method comprising administering to the cell an effective amount of inhibitor of late SV40 factor, wherein the inhibitor of late SV40 factor is a compound of claim 1 .
Assignees
Inventors
Classifications
the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom · CPC title
- C07D491/052Primary
the oxygen-containing ring being six-membered · CPC title
- A61P35/00Primary
Antineoplastic agents · CPC title
with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring · CPC title
the oxygen-containing ring being five-membered · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11420977B2 cover?
- The present invention is directed to compositions, methods and kits for treatment of cancer, e.g. heptacellular carcinoma (HCC). In some embodiments, the present invention discloses the use of a small-molecule compounds of Formula (I)-(V) to inhibit tubulin methylation or to modulate chromatin or cytoskeleton modification in a cell.
- Who is the assignee on this patent?
- Univ Boston
- What technology area does this patent fall under?
- Primary CPC classification C07D491/052. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Aug 23 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 6 related publications on this page (citations in our corpus or others sharing the same primary CPC).